Dr. Morgan on the Future of Myeloma Treatment

Gareth Morgan
Published: Friday, Jan 02, 2015



Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

 He advocates the investigation of unique treatment plans specifically targeted for each patient population. In the next one or two years, Morgan predicts that oncologists treating multiple myeloma will first do a sequence analysis to determine an individualized treatment based on the pattern of mutations seen in that patient. 

 His research has found that 50% of all the mutations within myeloma are actionable.



Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

 He advocates the investigation of unique treatment plans specifically targeted for each patient population. In the next one or two years, Morgan predicts that oncologists treating multiple myeloma will first do a sequence analysis to determine an individualized treatment based on the pattern of mutations seen in that patient. 

 His research has found that 50% of all the mutations within myeloma are actionable.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x